5.25
+0.01(+0.19%)
Currency In USD
| Previous Close | 5.24 |
| Open | 5.35 |
| Day High | 5.35 |
| Day Low | 5.16 |
| 52-Week High | 12.6 |
| 52-Week Low | 4.41 |
| Volume | 3,684 |
| Average Volume | 44,019 |
| Market Cap | 10.06M |
| PE | -0.24 |
| EPS | -22.21 |
| Moving Average 50 Days | 5.31 |
| Moving Average 200 Days | 6.04 |
| Change | 0.01 |
If you invested $1000 in Bolt Biotherapeutics, Inc. (BOLT) since IPO date, it would be worth $8.16 as of December 25, 2025 at a share price of $5.25. Whereas If you bought $1000 worth of Bolt Biotherapeutics, Inc. (BOLT) shares 3 years ago, it would be worth $201.92 as of December 25, 2025 at a share price of $5.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)
Newsfile
Oct 20, 2025 4:58 PM GMT
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the tre